Digital Agenda

None (Select only if you will not be attending any of the sessions listed above)

MTP Session I: AML        

Session Chair: Vitae Vyas        

• IDH Inhibition  |  Stéphane De Botton, MD  |  Institut de Cancérologie Gustave Roussy, Paris, France
• FLT3 Inhibition  |  Catherine Smith, MD  |  University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
• Approaches to Understand Mechanisms of Resistance and Response To AML Therapies Using Single Cell Approaches  |  Vitae Paresh Vyas, MRCPath, FRCP, FRCPath  |  Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

MTP Session II: ALL

Session Chair: Ching-Hon Pui        

• How The COG Is Approaching The High Risk Patient With ALL – Incorporation Of Immunotherapy Into Frontline Treatment  |  Jennifer McNeer, MD, MS  |  The University of Chicago Medicine, Chicago, Illinois, USA
• Management of Toxicity in AYAs with ALL  |  Kjeld  Schmiegelow, MD  |  Copenhagen University Hospital, Copenhagen, Denmark
• How to Use an MRD Result in AYAs Receiving Pediatric Regimens?  |  Aaron Logan, MD, PhD  |  UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA

MTP Session III: NHL  

Session Chair: Nathan Fowler        

• Role of Transplant in Lymphoma  |  Sonali M. Smith, MD, FASCO  |  The University of Chicago, Chicago, Illinois, USA
• CNS Lymphoma  |  Christopher R Flowers, MD, MS  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• What is the Optimal Frontline Regimen in FL  |  Nathan H. Fowler, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session IV: NHL

Session Chair: Laurie Sehn        

• Hodgkin Lymphoma  |  Pier Luigi Zinzani, MD  |  University of Bologna, Bologna, Italy
• Double Hit Lymphoma  |  Laurie Sehn, MD, MPH  |  BC Cancer, Vancouver, Canada
• CAR T-Cell Therapy for Lymphoma  |  Sattva S. Neelapu, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session V: CML

Session Chair: Jerry Radich

• Selecting the Right TKI | Jorge Cortés, MD | Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
• CML Management in Resource Limited Countries | Jerald P. Radich, MD | University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
• Is NGS Ready for Clinical Practice: Advantages and Limitations | Simona Soverini, MD | University of Bologna, Bologna, Italy

MTP Session VI: MPN      

Session Chair: Uday Popat        
CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?        

• A Young Woman with Thrombocytosis  |  Prithviraj Bose, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• A Young Man with Polycythemia Vera and Fatigue  |  Gabriela Hobbs, MD  |  Massachusetts General Hospital, Boston, Massachusetts, USA
• A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis  |  Uday Popat, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session VII: MDS        

Session Chair: Koichi Takahashi

• Pitfalls in Assessing Response to Treatment in MDS  |  Uwe Platzbecker, MD  |  Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany
• The Spectrum of Clonal Hematopoiesis from CHIP to AML  |  Koichi Takahashi, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• Challenges in Diagnosis and Risk Stratification of MDS  |  Aziz Nazha, MD  |  Cleveland Clinic, Cleveland, Ohio, USA

MTP Session VIII: MM        

Session Chair: Thomas Martin        

• Latest Treatment Approaches in AL Amyloidosis  |  Suzanne Lentzsch, MD, PhD  |  Columbia University and at New York Presbyterian Hospital, New York, USA
• Emerging Therapy  |  Thomas G. Martin, MD  |  University of California San Francisco, San Francisco, California, USA

MTP Session IX: CLL        

Session Chair: Emili Montserrat        

• BTK and Monoclonal Antibodies  |  Carol Moreno, MD, PhD  |  Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
• BTK and CIT  |  Philip A. Thompson, MB, BS  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• BTK and BCL2  |  Nitin Jain, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session X: Cellular Therapy (No CME credit for this session)        

Session Chair: Susan Prockop        

• CD19 CAR T Cells for Adults  |  David L. Porter, MD  |  University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
• EBV CTLs for PTLD– Ready for Prime Time  |  Susan Prockop, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
• Vaccines and Immunotherapy  |  David E. Avigan, MD  |  Beth Israel Deaconess Medical Center and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA

Exhibit Hall Experience

MTP Session XI: AML        

Session Chair: Courtney DiNardo        

• Changing the Treatment Paradigm in AML  |  Daniel Pollyea, MD, MS  |  University of Colorado, Denver, Colorado, USA
• Targeting the Microenvironment  |  Geoffrey L. Uy, MD  |  Washington University School of Medicine, St. Louis, Missouri, USA
• Familial AML  |  Courtney D. DiNardo, MD, MSCE  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session XII: ALL      

Session Chair: Elias Jabbour        

• How I Approach the Treatment of T-ALL in Adults in 2020  |  Nitin Jain, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• How I Treat the Older Adult with B-ALL  |  Elias Jabbour, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• How I Approach the Patient Who Has MRD Or Relapse After Transplant  |   Lori Muffly, MD  |  Stanford University Medical Center, Palo Alto, California, USA

MTP Session XIII: NHL      

Session Chair: Loretta Nastoupil        

• Primary Mediastinal Large Cell Lymphoma  |  Pier Luigi Zinzani, MD  |  University of Bologna, Bologna, Italy
• Role of Radiation Therapy in HL  |  Joachim Yahalom, MD, FACR  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA
• Chemo Free Regimens in Lymphoma  |  Loretta Nastoupil, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session XIV: NHL    

Session Chair: Ariela Noy        

• Strategies for Developing Novel Therapies and Aggressive Lymphomas  |  Christopher R. Flowers, MD, MS  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• Treatment of Early Stage DLBCL  |  Daniel O. Persky, MD  |  University of Arizona Cancer Center, Tucson, Arizona, USA
• Burkitt Lymphoma  |  Ariela Noy, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA

MTP Session XV: CML  

Session Chair: Jerry Radich        

• Selecting the Right TKI  |  Jorge Cortés, MD  |  Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
• CML Management in Resource Limited Countries  |  Jerald P. Radich, MD  |  University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
• Is NGS Ready for Clinical Practice: Advantages and Limitations  |  Simona Soverini, MD  |  University of Bologna, Bologna, Italy

MTP Session XVI: MPN      

Session Chair: Uday Popat        
CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?        

• A Young Woman with Thrombocytosis  |  Prithviraj Bose, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• A Young Man with Polycythemia Vera and Fatigue  |  Gabriela Hobbs, MD  |  Massachusetts General Hospital, Boston, Massachusetts, USA
• A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis  |  Uday Popat, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

MTP Session XVII: MDS    

Session Chair: Rami Komrokji        

• How Do I Treat: Lower Risk MDS  |  Valeria Santini, MD  |  University of Florence, Florence, Italy
• How Do I Treat: Higher Risk MDS  |  Rami Komrokji, MD  |  H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
• How Do I Treat: MDS/MPN  |  Eric Padron, MD  |  H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

MTP Session XVIII: MM  

Session Chair: Sheeba Thomas        

• Waldenstroms Macroglobunemia  |  Sheeba K. Thomas, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• Bone Diseases and Supportive Care  |  Jens Hillengass, MD  |  Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

MTP Session XIX: CLL

Session Chair: Phil Thompson        

• Managing BTK Inhibitor Toxicities  |  Alessandra Ferrajoli, MD  |  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
• Managing BCL2 Toxicities  |  John Seymour, MBBS, FRACP, PhD  |  Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, Australia
• Managing Cellular Therapy Toxicities  |  Jae Park, MD  |  Memorial Sloan Kettering Cancer Center, New York, New York, USA

MTP Session XX: CT

Session Chair: Sergio Giralt

• Point of Care CAR T Cells | Marcos de Lima, MD | UH Cleveland Medical Center, Cleveland, Ohio, USA
• CAR vs Transplant for NHL | Richard Maziarz, MD | Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA
• Role of CAR T Cells in Relapsed Myeloma | Andrzej Jakubowiak, MD, PhD | University of Chicago Medical Center, Chicago

Exhibit Hall Experience

Session I: Acute Lymphoblastic Leukemia

Session I: Acute Lymphoblastic Leukemia

Welcome and Opening Remarks | Sagar Lonial, MD, FACP | President, Society of Hematologic Oncology

Session I: Acute Lymphoblastic Leukemia

In Relapsed B-ALL, How Should We Best Sequence the New Targeted Agents? | Emily Curran, MD | The University of Cincinnati, Cincinnati, Ohio, USA

Session I: Acute Lymphoblastic Leukemia

Mini- Hyper – CVD Combinations for Older Adults: Results of Recent Trials and A Glimpse into the Future | Marlise R. Luskin, MD, MSCE | Dana Farber Cancer Institute, Boston, Massachusetts, USA

Session I: Acute Lymphoblastic Leukemia

Who Should Receive an Allogeneic Transplant in First Complete Remission? | Josep-Maria Ribera, MD, PhD | Catalan Institute of Oncology, Barcelona, Spain

Session I: Acute Lymphoblastic Leukemia

What’s the Latest Innovation in CAR-T Therapy? Fast-Off, Dual Targeting and Other New Tricks | Martin Pule, MB BCh, MRCP | Cancer Institute, University College London, London, United Kingdom

Session I: Acute Lymphoblastic Leukemia

Genomics of Drug Response in ALL: Predicting Response and Concerns for Triggering Relapse | Jun J. Yang, PhD |St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Session I: Acute Lymphoblastic Leukemia

DEBATE: Is Less More? Intensive vs Non-Intensive Approach to Adults with Ph+ ALL | Nicholas Short, MD | Sabina Chiaretti, MD, PhD

Session I: Acute Lymphoblastic Leukemia

Oral Abstract - ALL-312 | Saleem Eldadah, MD | Princess Noorah Oncology Center, Ministry of the National Guard - Health Affairs, Jeddah, Saudi Arabia

Industry Expert Session IA

An Acute Myeloid Leukemia Treatment Option for Patients | Hetty Carraway, MD, MBA | Cleveland Clinic, Cleveland, Ohio, USA

Industry Expert Session IB

A CAR T-cell Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma TECARTUS™ (brexucabtageneautoleucel) Prescribing Information  | David Rizzieri, MD | Duke University School of Medicine, Durham, North Carolina, USA

Exhibit Hall Experience

Plenary Session I

Keynote Speaker: Immunotherapy for T-Cell ALL and T-NHL | John DiPersio, MD, PhD | Washington University, St. Louis, Missouri, USA

Session II: Myelodysplastic Syndromes

New Approaches for Anemia in MDS | Uwe Platzbecker, MD | Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany

Session II: Myelodysplastic Syndromes

Session II: Myelodysplastic Syndromes

Development of Oral HMAs for MDS | Guillermo Garcia-Manero, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session II: Myelodysplastic Syndromes

Targeting BCL-2 in MDS | Amer Zeidan, MBBS | Yale Cancer Center, New Haven, Connecticut, USA

Session II: Myelodysplastic Syndromes

Targeting p53 in MDS | David Sallman, MD | H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Session II: Myelodysplastic Syndromes

IDH inhibitors in MDS | Courtney D. DiNardo, MD, MSCE | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session II: Myelodysplastic Syndromes

Oral Abstract - MDS-254 SF3B1 Splicing Mutation in the Context of Therapy-Related MDS | Virginia Volpe, MD | H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Exhibit Hall Experience

Session III: Acute Myeloid Leukemia

Session III: Acute Myeloid Leukemia

State of the Art in AML | Laura C. Michaelis, MD | Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Session III: Acute Myeloid Leukemia

Germline Mutations in AML | Coleman Lindsley, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Session III: Acute Myeloid Leukemia

Harnessing Apoptosis in AML | Marina Konopleva, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session III: Acute Myeloid Leukemia

The Problem of Mutant P53 AML | David Sallman, MD | H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Session III: Acute Myeloid Leukemia

Targeting CD123 in AML | Andrew A. Lane, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Session III: Acute Myeloid Leukemia

DEBATE: Fit Older Adults Between 60-75 in First Remission on Either Extreme of the Prognostic Spectrum Should Undergo Allo SCT | Edwin Pascal Alyea, MD | Duke University School of Medicine, Durham, North Carolina, USA

Session III: Acute Myeloid Leukemia

DEBATE: Fit Older Adults Between 60-75 in First Remission on Either Extreme of the Prognostic Spectrum Should Not Undergo Allo SCT | Uma Borate, MD, MS | Oregon Health & Science University, Portland, Oregon, USA

Session III: Acute Myeloid Leukemia

Novel Antibodies in AML | Marion Subklewe, MD | Ludwig-Maximilians-University of Munich, Munich, Germany

Session III: Acute Myeloid Leukemia

Oral Abstract - AML-063 A Randomized, Double-Blind, Placebo-Controlled Study in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A | Courtney D. DiNardo, MD, MSCE | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Poster Session & Awards

Chat with Poster Presenters and congratulate the Award winners.

Independent Satellite Symposium I

Relapsed/Refractory Multiple Myeloma: What’s Next for Patients? | Jesus Berdeja, MD, Tennessee Oncology | Joshua Richter, MD, Mount Sinai

Independent Satellite Symposium II

The Evolving Therapeutic Landscape in Relapsed Refractory Multiple Myeloma |Sagar Lonial, MD, FACP | Emory University, Atlanta, USA – Chair | Adam Cohen, MD | University of Pennsylvania, Philadelphia, USA | Shaji Kumar, MD | Mayo Clinic, Rochester, Minnesota, USA

Breakfast with the Expert I

CAR T for Myeloid Leukemias – Current Status | Elizabeth L. Budde, MD, PhD | City of Hope National Medical Center, Duarte, California, USA

Exhibit Hall Experience

Session IV: Myeloproliferative Neoplasms

Genomics in Myelofibrosis: Practical Guidelines for Its Use in Clinical Practice  | Raajit K. Rampal, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Session IV: Myeloproliferative Neoplasms

Session IV: Myeloproliferative Neoplasms

New Therapies in Development for Myelofibrosis  | Srdan Verstovsek, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session IV: Myeloproliferative Neoplasms

Improved Outcomes with Transplant for MPN  | Uday Popat, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session IV: Myeloproliferative Neoplasms

CASE PRESENTATION: Thrombosis in PV: How to Predict and How to Reduce the Risk  | Gabriela Hobbs, MD | Massachusetts General Hospital, Boston, Massachusetts, USA

Session IV: Myeloproliferative Neoplasms

CASE PRESENTATION: Post PV and Post ET MF: What A Doctor Needs to Know | Laura C. Michaelis, MD | Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Session IV: Myeloproliferative Neoplasms

Oral Abstract - MPN-188 Myeloablative Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors | Jacinth Joseph, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Exhibit Hall Experience

Session V: Multiple Myeloma

Session V: Multiple Myeloma

Frontline Therapy for Frail Older Patients | Brea C. Lipe, MD | The University of Rochester, Rochester, New York, USA

Session V: Multiple Myeloma

DEBATE: Frontline Therapy for Fit MM Patients Should Include an Antibody | Peter M. Voorhees, MD | Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA

Session V: Multiple Myeloma

DEBATE: Frontline Therapy for Fit MM Patients Should NOT Include an Antibody | Thomas G. Martin, MD | University of California San Francisco, San Francisco, California, USA

Session V: Multiple Myeloma

DEBATE: Smoldering MM Should Be Treated Early | Maria-Victoria Mateos, MD, PhD | University Hospital of Salamanca, Spain

Session V: Multiple Myeloma

DEBATE: Smoldering MM Should NOT Be Treated Early | Angela Dispenzieri, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

Session V: Multiple Myeloma

Role of HDT in Current Treatment for MM | Ajay K. Nooka, MD, MPH, FACP | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Session V: Multiple Myeloma

Management of Early Relapse | Robert Z. Orlowski, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session V: Multiple Myeloma

Oral Abstract - MM-350 Subgroup Analysis of GRIFFIN in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) | Ajay K. Nooka, MD, MPH, FACP | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Industry Expert Session IIA

IMMUNO-ONCOLOGY AND MDS: Current Knowledge and Future Perspectives | Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA |Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Industry Expert Session IIB

Intervening with Jakafi (ruxolitinib) to Achieve Durable Count Control: Real World Patient Case Discussion Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea | David Rizzieri, MD | Duke University School of Medicine, Durham, North Carolina, USA

Plenary Session II

BCMA Directed Therapy for MM | Nikhil C. Munshi, MD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Session VI: Chronic Lymphocytic Leukemia

Session VI: Chronic Lymphocytic Leukemia

Next Generation of BCR Inhibitors | Paolo Ghia, MD, PhD | Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

Session VI: Chronic Lymphocytic Leukemia

Measuring Residual Disease, Clinical Implications | William Wierda, MD, PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session VI: Chronic Lymphocytic Leukemia

What Is Fitness in the Era of Targeted Agents | Alessandra Tedeschi, MD | Niguarda Cancer Center, ASST Grande Ospedale Metropolitan Niguarda, Milan, Italy

Session VI: Chronic Lymphocytic Leukemia

DEBATE: BTK Inhibitor Is the Best Frontline Option for CLL | John C. Byrd, MD | The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Session VI: Chronic Lymphocytic Leukemia

DEBATE: BCL2 Inhibitor Is the Best Frontline Option for CLL | Michael Hallek, MD | University Hospital of Cologne, Cologne, Germany

Session VI: Chronic Lymphocytic Leukemia

Cellular Therapies in CLL | Elizabeth J. Shpall, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session VI: Chronic Lymphocytic Leukemia

Oral Abstract - CLL-091 ASCEND Final Results in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) | Paolo Ghia, MD, PhD | Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

Exhibit Hall Experience

Industry Expert Session III

A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients Resistant/Intolerant to Prior TKI Therapy | Jorge Cortés, MD | Georgia Cancer Center at Augusta University, Augusta, Georgia, USA

Industry Expert Session IV

A Case-based Discussion on Improving Outcomes in Patients with Newly Diagnosed Secondary AML | Usama Gergis, MD, MBA | Weill Cornell Medical College, New York, New York, USA

Independent Satellite Symposium III

Myeloproliferative Neoplasms: Integrating New Therapies Into Challenging Case Scenarios | Prithviraj Bose, MD - Chair | Ruben Mesa, MD | Raajit K. Rampal, MD, PhD

Independent Satellite Symposium IV

Achieving Innovation in CLL Care With BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum | William G. Wierda, MD, PhD | Philip A. Thompson, MB, MS | The University of Texas MD Anderson Cancer Center

Breakfast with the Expert II

How to Move Beyond RCHOP | Sandeep S. Dave, MD, MS | Duke University School of Medicine, Durham, North Carolina, USA

Exhibit Hall Experience

Session VII: Hodgkin Lymphoma

Newly Diagnosed HL | David J. Straus, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Session VII: Hodgkin Lymphoma

Session VII: Hodgkin Lymphoma

Relapsed HL | Alex F. Herrera, MD | City of Hope, Duarte, California, USA

Session VII: Hodgkin Lymphoma

Oral Abstract - HL-323 Outcomes of First-Line Treatment in Patients with Advanced Clinical Stage Classic Hodgkin Lymphoma and Human Immunodeficiency Virus Infection | Juan José Del Moral, MD | Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Session VIII: T-Cell Lymphoma

Session VIII: T-Cell Lymphoma

Pathology and Pathogenesis of T Cell Lymphoma | Francisco Vega, MD PhD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session VIII: T-Cell Lymphoma

Newly Diagnosed | Kerry Savage, MD | BC Cancer, Vancouver, Canada

Session VIII: T-Cell Lymphoma

Relapsed T Cell Lymphoma | Steven M. Horwitz, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Session VIII: T-Cell Lymphoma

Oral Abstract - TCL-127 Impact of Concomitant Steroids on Efficacy in MAVORIC Trial | Larisa J. Geskin, MD, FAAD | New York Presbyterian Hospital, New York, NY, USA

Exhibit Hall Experience

Session IX: Indolent B-Cell Lymphoma

Management of Newly Diagnosed FL | Mathias J. Rummel, MD, PhD | Justus-Liebig University-Hospital, Giessen, Germany

Session IX: Indolent B-Cell Lymphoma

Session IX: Indolent B-Cell Lymphoma

Session IX: Indolent B-Cell Lymphoma

Relapsed FL | Nathan H. Fowler, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session IX: Indolent B-Cell Lymphoma

Marginal Zone Lymphoma | Emanuele Zucca, MD | Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Session IX: Indolent B-Cell Lymphoma

Waldenstrom | Morie A. Gertz, MD | Mayo Clinic, Rochester, Minnesota, USA

Session IX: Indolent B-Cell Lymphoma

Oral Abstract - IBCL-344 Marginal Zone Lymphoma: Epidemiology and Outcomes in a Mexican Center | Rosana Córdova, MD | Instituto Nacional de Cancerología, Mexico City, Mexico

Industry Expert Session VA

Redefining Approaches in Frontline Chronic Lymphocytic Leukemia (CLL) Treatment Imbruvica® + Rituximab vs FCR: Head-to-Head- Data in Frontline CLL/SLL | Nakhle Saba, MD, Tulane University, New Orleans, Louisiana, USA | Ruemu Birhiray, MD, Hematology Oncology of Indiana, Indianapolis, Indiana

Industry Expert Session VB

Explore Yescarta®:  CAR T Therapy, for Patients in Your Practice | John Pagel, MD, PhD | Swedish Cancer Institute, Seattle, Washington, USA

Plenary Session III

My Take on Prognostication and Management of Essential Thrombocythemia | Ayalew Tefferi, MD | Mayo Clinic Rochester, Rochester Minnesota, USA

Session X: Aggressive B-Cell Lymphoma

Session X: Aggressive B-Cell Lymphoma

Novel Immunotherapeutic Agents in Aggressive B-NHL | Martin Hutchings, MD, PhD | The Finsen Center, National Hospital Copenhagen University Hospital, Copenhagen, Denmark

Session X: Aggressive B-Cell Lymphoma

Relapsed DLBCL | Sonali M. Smith, MD, FASCO | The University of Chicago, Chicago, Illinois, USA

Session X: Aggressive B-Cell Lymphoma

CAR T Cells | Peter Riedell, MD | University of Chicago Medicine, Chicago, Illinois, USA

Session X: Aggressive B-Cell Lymphoma

Oral Abstract - ABCL-256 Role of Radiotherapy Differs Between Stages for Primary Bone Large B-Cell Lymphoma: A Real-World Study | Shengling Ma, MD | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Exhibit Hall Experience

Session XI: Mantle Cell Lymphoma

Session XI: Mantle Cell Lymphoma

Frontline Treatment of Mantle Cell Lymphoma | Steven Le Gouill, MD, PhD | Nantes University Hospital, Nantes, France

Session XI: Mantle Cell Lymphoma

Relapsed MCL | Jonathon B. Cohen MD, MS | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Session XI: Mantle Cell Lymphoma

Oral Abstract - MCL-129 First-Line Targeted Combination in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study | Michael L. Wang, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session XII: Cellular Therapy

Session XII: Cellular Therapy

Adding Vaccines to the Immunotherapy Cocktail | David E. Avigan, MD | Beth Israel Deaconess Medical Center and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA

Session XII: Cellular Therapy

New CAR Designs | Renier J. Brentjens, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Session XII: Cellular Therapy

Optimizing Lymphodepletion Prior to CAR T Cell Therapy   | Elizabeth L. Budde, MD, PhD | City of Hope National Medical Center, Duarte, California, USA

Session XII: Cellular Therapy

Oral Abstract - CT-279 Story of Success of Haploidentical Hematopoietic Stem Cell Transplantation in Aplastic Anemia: A Systematic Review and Meta-Analysis of Clinical Outcome | Ghada ELGohary, MD | Ain Shams University, Cairo, Egypt

Industry Expert Session VI

XOSPATA® (gilteritmnib): A Targeted Therapeutic Approach for Relapsed/Refractory FLT3m+ AML Patients | Naval Daver, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Independent Satellite Symposium V

The Rise of Novel Antibodies in Multiple Myeloma: Exploring the Present and Future of Antibody-based Treatment From CD38 to BCMA | Sagar Lonial, MD, FACP | Robert Z. Orlowski, MD, PhD

Independent Satellite Symposium VI

Treating Multiple Myeloma in 2020 – Best Approaches to Optimizing Patient Outcomes | Robert Z. Orlowski, MD, PhD - Chair | María-Victoria Mateos, MD, PhD | Paul Richardson, MD

Breakfast with the Expert III

CML Update | Michael Deininger, MD, PhD | Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA

Independent Satellite Symposium VII

Discover the Role of Two Immunotherapies in Myeloma Treatment | Melhem M. Solh, MD | Northside Hospital Blood and Marrow Transplant and Leukemia Program

Exhibit Hall Experience

Session XIII: Chronic Myeloid Leukemia

CML: State of the Art Update | Delphine Rea, MD, PhD | Hôpital Saint Louis, Paris, France

Session XIII: Chronic Myeloid Leukemia

Session XIII: Chronic Myeloid Leukemia

New Therapeutic Options in CML | Jorge Cortés, MD | Georgia Cancer Center at Augusta University, Augusta, Georgia, USA

Session XIII: Chronic Myeloid Leukemia

Update on CML-Like Disorders | Nick Cross, MA, PhD, FRCPath | University of Southampton, Salisbury, United Kingdom

Session XIII: Chronic Myeloid Leukemia

Case Studies: The Challenges of TFR | Timothy P. Hughes, MD, FRACP, FRCPA | South Australian Health and Medical Research Institute, Adelaide, Australia

Session XIII: Chronic Myeloid Leukemia

The Molecular Complexity of CML | Jerald P. Radich, MD | University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Session XIII: Chronic Myeloid Leukemia

Oral Abstract - CML-109 Exploratory Biomarker Analysis From ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) From Poor Response in Chronic Myeloid Leukemia (CML) | Jerald P. Radich, MD | University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Exhibit Hall Experience

Session XIV: Next Questions

Next Questions: Acute Lymphoblastic Leukemia | Selina M. Luger, MD | University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA

Session XIV: Next Questions

Session XIV: Next Questions

Next Questions: Acute Myeloid Leukemia | Amer Zeidan, MBBS | Yale Cancer Center, New Haven, Connecticut, USA

Session XIV: Next Questions

Next Questions: Cellular Therapy | Sergio Giralt, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Session XIV: Next Questions

Next Questions: Myelodysplastic Syndromes | Guillermo Garcia-Manero, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Session XIV: Next Questions

Next Questions: Chronic Myeloid Leukemia | Michael Deininger, MD, PhD | Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA

Session XIV: Next Questions

Next Questions: Aggressive B-Cell Lymphoma | Sandeep S. Dave, MD, MS | affiliation

Session XIV: Next Questions

Next Questions: Indolent B-Cell Lymphoma | Robert Marcus, MA, FRCP, FRCPath | Leaders in Oncology Care, London, United Kingdom

Session XIV: Next Questions

Next Questions: T-Cell Lymphoma | Kerry Savage, MD | BC Cancer, Vancouver, Canada

Session XIV: Next Questions

Next Questions: Mantle Cell Lymphoma | Jonathon B. Cohen, MD, MS | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Session XIV: Next Questions

Next Questions: Hodgkin Lymphoma | David J. Straus, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Session XIV: Next Questions

Next Questions: Multiple Myeloma | Sagar Lonial, MD, FACP | Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

Session XIV: Next Questions

Next Questions: Chronic Lymphocytic Leukemia | Jennifer R. Brown, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Session XIV: Next Questions

Next Questions: Myeloproliferative Neoplasms | Dr. Prithviraj Bose, MD | The University of Texas MD Anderson Cancer Center, Houston, Texas, USA